alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>
                                                                   Exhibit 99.01

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Quarterly Report on Form 10-Q of PLATO Learning, Inc.
(the "Company") for the period ended January 31, 2003, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), each of
John Murray, the President and Chief Executive Officer of the Company, and
Gregory J. Melsen, the Chief Financial Officer of the Company, hereby certify,
pursuant to and for purposes of 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:

      1. The Report fully complies with the requirements of Section 13(a) or
         15(d) of the Securities Exchange Act of 1934; and

      2. The information contained in the Report fairly presents, in all
         material respects, the financial condition and results of operations of
         the Company.


Date: March 17, 2003                  /s/ John Murray
                                      ----------------------------------
                                      President and
                                      Chief Executive Officer

                                      /s/ Gregory J. Melsen
                                      ----------------------
                                      Vice President Finance and
                                      Chief Financial Officer
CERTIFICATION PURSUANT TO THE SARBANES-OXLEY ACT
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

I, Dennis Hanks, Vice President, Principal Financial Officer of English
Language Learning and Instruction System, Inc. (the "Company") do hereby
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1.  This Annual Report on Form 10-KSB of the Company for the fiscal year ended
December 31, 2003, as filed with the Securities and Exchange Commission (the
"report"), fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

2.  The information contained in the report fairly presents, in all material
respects, the financial condition and results of operations of the Company.

Date:    March 26, 2004

/s/ Dennis Hanks
- ----------------------
Dennis Hanks
Vice President
and Principal Financial Officer
No. 87-6578.

#### Bush *v.*Petsock, Superintendent, State Correctional Institution and Diagnostic and Classification Center at Pittsburgh.

C. A. 3d Cir. Certiorari denied.
[Federal Register Volume 75, Number 210 (Monday, November 1, 2010)]
[Notices]
[Page 67145]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-27646]


-----------------------------------------------------------------------

OVERSEAS PRIVATE INVESTMENT CORPORATION


Sunshine Act: Public Hearing

TIME AND DATE: 2 p.m., Wednesday, November 24, 2010.

PLACE: Offices of the Corporation, Twelfth Floor Board Room, 1100 New 
York Avenue, NW., Washington, DC.

STATUS: Hearing open to the Public at 2 p.m.

PURPOSE: Public Hearing in conjunction with each meeting of OPIC's 
Board of Directors, to afford an opportunity for any person to present 
views regarding the activities of the Corporation.

pROCEDURES: Individuals wishing to address the hearing orally must 
provide advance notice to OPIC's Corporate Secretary no later than 5 
p.m. Thursday, November 18, 2010. The notice must include the 
individual's name, title, organization, address, and telephone number, 
and a concise summary of the subject matter to be presented.
    Oral presentations may not exceed ten (10) minutes. The time for 
individual presentations may be reduced proportionately, if necessary, 
to afford all participants who have submitted a timely request an 
opportunity to be heard.
    Participants wishing to submit a written statement for the record 
must submit a copy of such statement to OPIC's Corporate Secretary no 
later than 5 p.m. Thursday, November 18, 2010. Such statement must be 
typewritten, double-spaced, and may not exceed twenty-five (25) pages.
    Upon receipt of the required notice, OPIC will prepare an agenda, 
which will be available at the hearing, that identifies speakers, the 
subject on which each participant will speak, and the time allotted for 
each presentation.
    A written summary of the hearing will be compiled, and such summary 
will be made available, upon written request to OPIC's Corporate 
Secretary, at the cost of reproduction.
    Written summaries of the projects to be presented at the December 
9, 2010 Board meeting will be posted on OPIC's Web site on or about 
Thursday, November 4, 2010.

CONTACT PERSON FOR INFORMATION: Information on the hearing may be 
obtained from Connie M. Downs at (202) 336-8438, via facsimile at (202) 
218-0136, or via email at <a href="/cdn-cgi/l/email-protection#03606c6d6d6a662d676c746d70436c736a602d646c75"><span class="__cf_email__" data-cfemail="bdded2d3d3d4d893d9d2cad3cefdd2cdd4de93dad2cb">[email protected]</span></a>.

    Dated: October 28, 2010.
Connie M. Downs,
OPIC Corporate Secretary.
[FR Doc. 2010-27646 Filed 10-28-10; 4:15 pm]
BILLING CODE 3210-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
{"version":"1.0","provider_name":"NASA","provider_url":"https:\/\/www.nasa.gov","author_name":"Julia L. Bradshaw","author_url":"https:\/\/www.nasa.gov\/author\/julia-l-bradshawnasa-gov\/","title":"NASA Selects University Teams to Compete in 2024 RASC-AL Competition","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"9p8LzTIFBX\"><a href=\"https:\/\/www.nasa.gov\/centers-and-facilities\/langley\/nasa-selects-university-teams-to-compete-in-2024-rasc-al-competition\/\">NASA Selects University Teams to Compete in 2024 RASC-AL Competition<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.nasa.gov\/centers-and-facilities\/langley\/nasa-selects-university-teams-to-compete-in-2024-rasc-al-competition\/embed\/#?secret=9p8LzTIFBX\" width=\"600\" height=\"338\" title=\"“NASA Selects University Teams to Compete in 2024 RASC-AL Competition” — NASA\" data-secret=\"9p8LzTIFBX\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","thumbnail_url":"https:\/\/www.nasa.gov\/wp-content\/uploads\/2023\/07\/2024-rasc-al-website-header-graphic-11-x-5-in.png?w=600","thumbnail_width":600,"thumbnail_height":273}
#### Caldwell, Hunter & Co. *v.*Washington Dawson.

Pleadings — Amended Petition — Limitation.

Limitation does not run against an amended petition which only supplies a defect in the original, as the orginal was not barred by time.

New Trial.

A new trial should be granted where the verdict greatly exceeds the amount justly receivable.

APPEAL PROM HARDIN CIRCUIT COURT.

June 14, 1867.

Opinion op the Court by

Judge Robertson :

The original petition on the written contracts embraced also the extra coal not stipulated for in them, and sought judgment for all the coal delivered. But, as that petition contained no allegation of a contract as to the surplus coal delivered and sued for, or oi the value of it rendered an implied contract, this court decided that, on that petition as so framed, no judgment for more than 100,000 bushels covenanted for could be sustained. The subsequent amendment only supplied that defect, and thereby made the original-petition good for all the coal which had been delivered. The original petition was the commencement of the action for all the coal, as well the surplus as the covenant coal, and, in no sense, was the filing of the amendment charging the value of the surplus coal the institution of a new suit. As time did not bar the original, it does not bar the amended petition.

There was therefore no error in striking from the answer the plea of limitation, which was contradicted by the record. But *101tbe Circuit Court erred in over-ruling tlie motion for a new trial on the ground that, according to any rational deduction from the testimony, the verdict was excessive.

Measured at the place of delivery, and by the standard prescribed by the former opinion of this court, the quantity of coal delivered beyond the written contracts could not, according to any allowable deduction, amount in value to half the amount of the verdict. And it is quite clear that, even if interest had been allowed by the jury, their verdict greatly exceeds the amount justly recoverable on any consistent hypothesis.

Wherefore, the judgment is reversed, and the cause remanded for a new trial.
EXHIBIT
31.2
 
 I, Carl
Gessner, President, Secretary, Treasurer and Chief Financial Officer certify
that:
 
 1. I have
reviewed this annual report on Form 10-KSB of Senticore, Inc.
 
 2. Based
on my knowledge, the report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this annual report;
 
 3. Based
on my knowledge, the financial statements, and other financial information
included in this annual report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this annual report;
 
 4. The
registrant's other certifying officers and I am responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a-14 and 15d-14) for the registrant and have:
 
 a)
designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this annual report is being prepared;
 
 b)
evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this annual
report ("Evaluation Date"); and
 
 c)
presented in this annual report our conclusions about the effectiveness of the
disclosure controls and procedures based on our evaluation as of the Evaluation
Date;
 
 5. The
registrant's other certifying officers and I have disclosed, based on our most
recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):
 
 a) all
significant deficiencies in the design or operation of internal controls which
could adversely affect the registrant's ability to record, process, summarize
and report financial data and have identified for the registrant's auditors any
material weaknesses in internal controls (all of which do not apply);
and
 
 b) any
fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant's internal controls (all of which do
not apply); and
 
 6. The
registrant's other certifying officers and I have indicated in this quarterly
report whether there were significant changes in internal controls or in other
factors that could significantly affect internal controls subsequent to the date
of our most recent evaluation, including any corrective actions with regard to
significant deficiencies and material weaknesses (all of which do not
apply).
 
 Date:
April 15, 2005
 
 
 
 /s/ Carl
Gessner
 ________________________
 Carl
Gessner
 President,
Secretary, Treasurer and Chief Financial Officer
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THE FINANCIAL DATA SCHEDULE CONTAINS SUMMARY INFORMATION EXTRACTED FROM THE
TRUSTS FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER>                    1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                              79
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                    79
<PP&E>                                          87,276
<DEPRECIATION>                                  53,143 
<TOTAL-ASSETS>                                  34,212 
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<COMMON>                                             0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                      34,212
<TOTAL-LIABILITY-AND-EQUITY>                    34,212
<SALES>                                              0
<TOTAL-REVENUES>                                 8,664
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                   325  
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     8,339
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
<PAGE>

                                      EXHIBIT 4(E)
<PAGE>

     RESOLVED, that, subject to stockholder approval if required by applicable
Nasdaq rules, the Corporation shall pay, (i) on and as of the last day of the
month in which the annual meeting of stockholders is held in each calendar year
commencing 1998, to each non-employee director of the Corporation elected at
such meeting, an annual retainer equal to a number of shares of Common Stock
with a fair market value on such date (determined in a manner consistent with
the provisions of the Corporation's 1994 Stock Option Plan) of $10,000, (ii) on
and as of the last day of the month in which the 1998 Annual Meeting of
Stockholders is held (the "1998 Issue Date"), to each person who served as a
non-employee director of the Corporation from the time of the Corporation's
initial public offering through the date of the 1998 Annual Meeting of
Stockholders, a retainer equal to the number of shares of Common Stock with a
fair market value of $10,000 (determined in a manner consistent with the
provisions of the Corporation's 1994 Stock Option Plan) based on the higher of
(A) the fair market value per share of Common Stock on September 19, 1997 and
(B) the fair market value per share of Common Stock on the 1998 Issue Date, and
(iii) on and as of the last day of the month in which any newly appointed non-
employee director is appointed after the annual meeting of stockholders in any
year (provided that such director is appointed to serve for a period of at least
six months prior to the next annual meeting of stockholders), to such newly
appointed director, a retainer equal to a number of shares of Common Stock with
a fair market value on such date (determined in a manner consistent with the
provisions of the Corporation's 1994 Stock Option Plan) of $10,000; and it was
further

     RESOLVED, that, commencing on the date of the 1998 Annual Meeting of
Stockholders, the Corporation pay to each non-employee director attending
(either in person or via conference telephone call) any regular or special
meeting of the Board of Directors of the Corporation, a cash fee of $1,000; and
it was further

     RESOLVED, that, commencing on the date of the 1998 Annual Meeting of
Stockholders, the Corporation pay to each non-employee director attending
(either in person or via conference telephone call) any regular or special
meeting of any Committee of the Board of Directors of the Corporation of which
such director is a member, a cash fee of $500; provided, that no such fee shall
be payable with respect to any Committee meeting if such meeting takes place on
the same day as a regular or special meeting of the Board of Directors; and it
was further

     RESOLVED, that the proper officers of the Corporation be, and each of them
hereby is, authorized and empowered, in the name and on behalf of the
Corporation, to execute all such documents or instruments, in order to carry out
each of the foregoing resolutions and to effectuate the purposes and intents
thereof.
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration [Docket No. DEA-392]
 ACTION: Notice of application.
 DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before November 7, 2014. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before November 7, 2014.
 ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152. Request for hearings should be sent to: Drug Enforcement Administration, Attention: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.


SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of importers, of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (“Deputy Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, subpart R, App. In accordance with 21 CFR 1301.34(a), this is notice that on December 13, 2013, Fisher Clinical Services, Inc., 700A-C Nestle Way, Breinigsville, Pennsylvania 18031-1522 applied to be registered as an importer of the following basic classes of controlled substances: Controlled substance
ScheduleMethylphenidate (1724)
IILevorphanol (9220)
IINoroxymorphone (9668)
IITapentadol (9780)
II
 The company plans to import the listed substances for analytical research, testing, and clinical trials. This authorization does not extend to the import of a finished FDA approved or non-approved dosage form for commercial distribution in the United States. The company plans to import an intermediate form of tapentadol (9780) to bulk manufacture tapentadol for distribution to its customers. Dated: October 1, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator.


[FR Doc. 2014-24081 Filed 10-7-14; 8:45 am] BILLING CODE 4410-09-P
{"version":"1.0","provider_name":"NASA","provider_url":"https:\/\/www.nasa.gov","author_name":"Robert E. Lewis","author_url":"https:\/\/www.nasa.gov\/author\/robert-e-lewisnasa-gov\/","title":"Flight Surgeons","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"2G1X1VD5XI\"><a href=\"https:\/\/www.nasa.gov\/directorates\/esdmd\/hhp\/flight-surgeons\/\">Flight Surgeons<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.nasa.gov\/directorates\/esdmd\/hhp\/flight-surgeons\/embed\/#?secret=2G1X1VD5XI\" width=\"600\" height=\"338\" title=\"“Flight Surgeons” — NASA\" data-secret=\"2G1X1VD5XI\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","thumbnail_url":"https:\/\/www.nasa.gov\/wp-content\/uploads\/2023\/03\/hhp-flight-surgeon-console-jsc2010e021379.jpeg?w=600","thumbnail_width":600,"thumbnail_height":450}